Page 99 - 2021_06-Haematologica-web

Improved outcomes for non-myeloablative allo-HCT
high); multiple myeloma diagnosis; AML diagnosis; CMV serosta- tus (recipient and donor negative, recipient and/or donor positive); donor relation (related, unrelated); sex mismatch (female to male, others); prior HCT (no, yes); HLA-allele mismatch (no, yes); HCT- CI (0, 1–2, 3, ≥4, or missing). All P-values were two-sided and are unadjusted for multiple comparisons.
Results
Study population
Our study population of 1,720 total patients in three ter- tiles is summarized in Table 1 and consisted of 562 patients who underwent HCT during the period from
Table 1. Transplant and patient characteristics by transplant era.
1997–2003 2004–2009 2010–2017
P
Transplant characteristics
Conditioning regimena
TBI2Gy 127 33
99 17 454 76 37 6
53 9 283 50 173 31
Donord
Related 371 Unrelated 191
Disease risk groupe
Low 129 Standard 270 High 163
Age, years
≤49 174 50–59 236 ≥60 152
Sex match
Female to male 169 Others 393
CMV serostatus
R–/D– 129 R+/D– 141 R+/D+ 84
R–/D+
HCT-CIf
1,2
3
≥4 Missing
HLA-allele mismatchg No
Yes
Prior HCTh No
Yes
66 249 42 197 35
34 345 58 367 65
(n=562) (n=594) (n=564) n%n%n%
TBI 2 Gy + fludarabine 435 TBI 3 Gy + fludarabine
TBI 4 – 4.5 Gy + fludarabine
TBI 2 Gy + clofarabine
77
GVHD prophylaxisb
CI+MMF 562 100 CI + MMF + sirolimus
4116 3
40 7
529 89 451 80 65 11 113 20
208 35 130 23 327 55 333 59
Patient characteristics
Center / treatmentc Non-FH on-protocol FH on-protocol FHoff-protocol
Diagnosis ALL
AML
CLL
CML
HL MDS/MPN MM
NHL WM
287 51 264 47
< 0.0001
< 0.0001
< 0.0001
11 2 59
10 101 18
17 330545 8 90 16 184 31 167 30 62 11 65 11 73 13 39 7 12 2 6 1 34 630517 3
84 15 71 12 129 22 95 16 101 18 101 17
90 16 56 10 107 19
61612<1
23 131 22 169 48 297 50 276 29 166 28 118
31 131 22 102 42 208 35 147 27 255 43 316
30 137 23 141 70 457 77 423
23 172 29 169 25 172 29 158 15 73 12 68
30 0.002 49
21
18 <0.0001 26
56
25 0.04 75
27 20 25 18
94 0.72
6
30 0.02 28
12
30
208 37 177 30 169
0 1182189155610<0.0001
129 23 137 23 152 73 13 131 22 113 67 12 125 21 141 174 31 113 19 102
534 95 552 93 530
28 542734
427 76 416 70 433 77 0.008 135 24 179 30 131 23
continued on next page
haematologica | 2021; 106(6)
1601